Skip to main content

CDC panel to review booster for children aged 5 to 11 as U.S. cases climb 57% from two weeks ago

A Centers for Disease Control and Prevention panel will meet to review a third dose of the vaccine developed by Pfizer and BioNTech for children aged 5 to 11.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.